Sonnet BioTherapeutics (SONN) News Today $0.86 +0.01 (+1.18%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period July 25 at 11:07 AM | finanznachrichten.deJTC Team, LLC: Sonnet BioTherapeutics Participates in Virtual Investor "What This Means" Segment Hosted by JTC TeamJuly 24 at 8:30 AM | globenewswire.comSonnet BioTherapeutics Reports Encouraging Data from Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) That Support Advancement into Phase 2 StudyMay 28, 2024 | globenewswire.comSonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual MeetingMay 22, 2024 | finanznachrichten.deSonnet BioTherapeutics, Inc.: Sonnet BioTherapeutics Announces Review of Strategic AlternativesMay 22, 2024 | finance.yahoo.comSonnet BioTherapeutics Announces Review of Strategic AlternativesMay 15, 2024 | investorplace.comSONN Stock Earnings: Sonnet BioTherapeutics Misses EPS for Q2 2024April 28, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Cullinan Management (CGEM) and HCA Healthcare (HCA)April 17, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Legend Biotech (LEGN), Genmab (GMAB)April 12, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Bausch Health Companies (BHC) and Arcus Biosciences (RCUS)March 11, 2024 | finance.yahoo.comSonnet BioTherapeutics Announces Early Safety Data from the Company’s Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study’s Initial Pre-Specified ObjectiveMarch 1, 2024 | morningstar.comSonnet BioTherapeutics Holdings Inc Ordinary Shares SONNFebruary 29, 2024 | finanznachrichten.deSonnet BioTherapeutics, Inc.: Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy VolunteersFebruary 29, 2024 | msn.comSonnet BioTherapeutics Reported SON-1010 Phase I Trial Results: Demonstrates Safety, Efficacy in Melanoma Model, and Potential for Dose EscalationFebruary 17, 2024 | finance.yahoo.comSonnet BioTherapeutics Holdings First Quarter 2024 Earnings: Beats ExpectationsFebruary 14, 2024 | finance.yahoo.comSonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings UpdateFebruary 7, 2024 | msn.comNasdaq panel expected to decide on Yield10 listing within next monthJanuary 1, 2024 | markets.businessinsider.comBTIG Keeps Their Buy Rating on Sonnet BioTherapeutics Holdings (SONN)December 22, 2023 | msn.comSonnet BioTherapeutics files for $100M mixed shelfDecember 21, 2023 | finance.yahoo.comSonnet BioTherapeutics Announces Publication Demonstrating Suitability of SON-1210, the First Albumin-binding Bifunctional IL-12/IL-15 Fusion Protein, for Solid Tumor ImmunotherapyDecember 16, 2023 | markets.businessinsider.comBuy Rating Affirmed for Sonnet BioTherapeutics Amid Promising Oncology Trials and Financial FortitudeDecember 14, 2023 | finance.yahoo.comSonnet BioTherapeutics Provides Fiscal Year 2023 Business and Financial UpdateOctober 31, 2023 | finance.yahoo.comSonnet BioTherapeutics Provides Fiscal Year 2023 Business OverviewOctober 26, 2023 | benzinga.comWhat's Happening With Sonnet BioTherapeutics (SONN) Shares?October 25, 2023 | markets.businessinsider.comDow Falls Over 100 Points; Alphabet Shares Tumble After Q3 ResultsOctober 25, 2023 | msn.comSonnet BioTherapeutics down 32%, prices $4.55M stock offeringOctober 25, 2023 | benzinga.comWhy Sonnet BioTherapeutics (SONN) Stock Is Getting HammeredOctober 25, 2023 | marketwatch.comSonnet BioTherapeutics Shares Slide Premarket After Stock OfferingOctober 25, 2023 | msn.comWhy Is Sonnet BioTherapeutics (SONN) Stock Down 33% Today?October 25, 2023 | finance.yahoo.comSonnet BioTherapeutics Announces Pricing of $4.55 Million Underwritten Public OfferingOctober 17, 2023 | finance.yahoo.comSonnet BioTherapeutics Announces Abstract Accepted for Presentation by a Key Opinion Leader at the 2023 Connective Tissue Oncology Society (CTOS) Annual MeetingOctober 17, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Ambrx Biopharma (AMAM) and Aldeyra Therapeutics (ALDX)September 20, 2023 | finance.yahoo.comSonnet BioTherapeutics Announces Results of Biodistribution Studies Demonstrating Solid Tumor Targeting Using the FHAB TechnologySeptember 19, 2023 | msn.comSonnet BioTherapeutics regains listing complianceSeptember 19, 2023 | finance.yahoo.comSonnet BioTherapeutics Regains Nasdaq Minimum Bid Price ComplianceSeptember 1, 2023 | marketbeat.comTrading was temporarily halted for "SONN" at 10:09 AM with a stated reason of "LULD pause." Trading set to resume at 10:09 AM. September 1, 2023 | marketbeat.comTrading was temporarily halted for "SONN" at 09:09 AM with a stated reason of "LULD pause."August 31, 2023 | msn.comSonnet BioTherapeutics launches 1-for-22 reverse stock splitAugust 31, 2023 | benzinga.comWhy Sonnet BioTherapeutics Stock (SONN) Is Getting ObliteratedAugust 31, 2023 | finance.yahoo.comSonnet BioTherapeutics Announces 1-for-22 Reverse Stock SplitAugust 17, 2023 | markets.businessinsider.comChardan Capital Keeps Their Buy Rating on Sonnet BioTherapeutics Holdings (SONN)August 16, 2023 | marketwatch.comSonnet BioTherapeutics Shares Rise After FDA Approves Drug TrialAugust 16, 2023 | finance.yahoo.comSonnet BioTherapeutics Announces FDA Acceptance of the Company's IND for the SB221 Clinical Trial of SON-1010 Combined with Atezolizumab in the USAugust 14, 2023 | finanznachrichten.deSonnet BioTherapeutics, Inc.: Sonnet BioTherapeutics Provides Fiscal Year 2023 Third Quarter Business and Earnings UpdateAugust 14, 2023 | finance.yahoo.comSonnet BioTherapeutics Provides Fiscal Year 2023 Third Quarter Business and Earnings UpdateJuly 31, 2023 | investorplace.comWhy Is Sonnet BioTherapeutics (SONN) Stock Down 5% Today?July 31, 2023 | finanznachrichten.deSonnet BioTherapeutics, Inc.: Sonnet BioTherapeutics to Present at the 2023 BTIG Virtual Biotechnology ConferenceJuly 31, 2023 | finance.yahoo.comSonnet BioTherapeutics to Present at the 2023 BTIG Virtual Biotechnology ConferenceJuly 3, 2023 | finance.yahoo.comBeat the Market the Zacks Way: Vertiv, Costco, Sonnet BioTherapeutics in FocusJune 29, 2023 | seekingalpha.comSonnet BioTherapeutics stock plummets 20% on $2.25M registered direct offeringJune 28, 2023 | msn.comWhy Sonnet BioTherapeutics (SONN) Stock Is Nosediving Get Sonnet BioTherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SONN and its competitors with MarketBeat's FREE daily newsletter. Email Address 625,000% Gain (Ad)Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz. >> Dive into the Workshop Here SONN Media Mentions By Week SONN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SONN News Sentiment▼0.410.62▲Average Medical News Sentiment SONN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SONN Articles This Week▼40▲SONN Articles Average Week Get Sonnet BioTherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SONN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: PHAXIAM Therapeutics News Today Alterity Therapeutics News Today TC Biopharm News Today GeoVax Labs News Today TransCode Therapeutics News Today BioCardia News Today Lixte Biotechnology News Today Ainos News Today Artelo Biosciences News Today Psyence Biomedical News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SONN) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sonnet BioTherapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sonnet BioTherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.